Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)
ID: 357183Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357183

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-040.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory research on schizophrenia and related disorders in individuals aged 35 and older, through the R21 grant mechanism. This initiative aims to enhance understanding of the onset, trajectory, and outcomes of these disorders in mid- to late-life, encouraging innovative studies that identify biological, behavioral, and environmental risk factors, as well as potential interventions. The funding, which can reach up to $275,000 over a maximum of two years, is crucial for addressing health disparities faced by older adults with these disorders and promoting novel solutions for their care. Applications are due between January 2025 and October 2026, and interested parties can contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-040.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is issuing a funding opportunity for exploratory research regarding schizophrenia and related psychotic disorders in individuals aged 35 and older. This initiative aims to enhance understanding of the onset, trajectory, and outcomes of these disorders in mid- to late-life, encouraging innovative studies that identify biological, behavioral, and environmental risk factors and potential interventions. The R21 grant mechanism is appropriate for high-risk projects without preliminary data, while the R01 mechanism supports those with established data seeking longer-term funding. Applications should integrate diverse research methodologies, involve interdisciplinary teams, and leverage advanced technologies, including high-field neuroimaging. Eligible applicants include various educational and nonprofit institutions, among others, and the funding can reach up to $275,000 over a maximum of two years. Applications are due between January 2025 and October 2026, with emphasis on compliance with application guidelines to ensure review. This opportunity is essential for addressing the significant health disparities faced by older adults with these disorders, promoting novel solutions and enhancing care.
    Similar Opportunities
    Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Schizophrenia and Related Disorders During Mid- to Late-Life" (PAR-24-026), aimed at advancing research on the onset and progression of schizophrenia and related disorders in individuals aged 35 and older. This initiative seeks to promote high-risk exploratory and developmental projects that investigate neurobiological, psychosocial, and environmental factors contributing to these disorders, with a particular emphasis on addressing health disparities among minority and aging populations. The program offers a maximum funding amount of $275,000 over two years, with applications due by November 16, 2023, for the initial cycle. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Schizophrenia and Related Disorders During Mid- to Late-Life," aimed at advancing research on the emergence and trajectory of schizophrenia and related disorders in individuals aged 35 and older. This initiative seeks to identify biological, psychosocial, and environmental mechanisms affecting this population to develop effective prevention and treatment strategies, addressing a critical gap in mental health research. The funding utilizes the R01 grant mechanism, with applications accepted starting January 5, 2025, and a project period of up to five years. Eligible applicants include a wide range of institutions and organizations, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov. The application deadline is September 7, 2026.
    Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)" aimed at advancing research on schizophrenia and related disorders in individuals aged 35 and older. This initiative seeks to explore the mechanisms, trajectories, and outcomes of these disorders, with a focus on identifying targets for prevention and treatment interventions, particularly emphasizing the inclusion of diverse research teams and individuals with lived experience. The funding is available through the R01 grant mechanism, with applications due by September 7, 2026, and interested applicants are encouraged to adhere strictly to the application guidelines and contribute data to the National Institute of Mental Health Data Archive. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-023.html.
    Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for multidisciplinary research on HIV/AIDS and aging through the R21 Exploratory/Developmental Research Grant program. This initiative invites applications that aim to enhance the understanding of the biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, with specific objectives to improve prevention, testing, treatment strategies, and management of HIV-related health issues in diverse populations, particularly older adults aged 70 and above. The grant provides funding of up to $275,000 for a two-year period, with key submission dates starting April 4, 2024, and a closing date for applications set for January 7, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the R21 exploratory research grant focused on understanding neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD). This funding opportunity aims to enhance knowledge of the neurobiological and behavioral mechanisms underlying symptoms such as aggression, anxiety, and agitation, which significantly impact patient care and outcomes. The initiative is part of a broader national effort to address the complexities of Alzheimer's care, with funding capped at $275,000 over two years, and applications opening on January 16, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)" aimed at encouraging research into high-confidence risk factors associated with complex brain disorders such as schizophrenia, bipolar disorder, and major depression. This initiative supports exploratory developmental research (R21) to identify molecular, cellular, and circuit mechanisms involved in these disorders, utilizing diverse experimental paradigms without the necessity for prior feasibility data. The funding amount is capped at $275,000 over two years, with a maximum of $200,000 per year, and eligible applicants include a wide range of educational institutions, nonprofits, and for-profit organizations. Interested parties can find more information and application details at the NIH website, with the application deadline set for September 7, 2026.
    Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional) to support innovative and exploratory research projects in neuroscience. This grant aims to facilitate early-stage studies that assess novel avenues of investigation, particularly those that may involve significant risk but hold the potential for breakthroughs in understanding neuroscience or developing new methodologies. Eligible applicants include a wide range of organizations such as educational institutions, nonprofits, and tribal governments, with funding available up to $200,000 over two years. Interested parties should submit their applications by January 7, 2025, and can find additional information and application guidelines at the NIH website or contact grantsinfo@nih.gov for assistance.
    NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Mental Health (NIMH), is offering the Exploratory/Developmental Research Grant (R21), which aims to support high-risk and innovative research projects that align with the mission of advancing mental health research. This grant is specifically designed for the early stages of research that may lead to significant breakthroughs in clinical and biomedical fields related to mental health, with a funding limit of $275,000 over a two-year period. Eligible applicants include a diverse range of organizations such as higher education institutions, non-profits, and tribal governments, emphasizing the importance of innovative approaches in addressing critical barriers in mental health research. Interested parties should note that applications are due by January 7, 2025, and must adhere to NIH guidelines, with further inquiries directed to grantsinfo@nih.gov.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia," aimed at enhancing the understanding of neuropsychiatric symptoms associated with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). This initiative invites exploratory research to identify the neurobiological and behavioral pathways that contribute to symptoms such as aggression, depression, anxiety, and agitation, with the goal of discovering novel therapeutic approaches for treatment. The funding, available through the R21 grant mechanism, supports diverse methodologies and interdisciplinary collaboration, with a maximum budget of $275,000 over two years. Applications are due by September 7, 2026, and eligible applicants include a wide range of institutions and organizations, including educational institutions, non-profits, and foreign entities. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) to support innovative early-stage research projects that may lead to significant advancements in biomedical, behavioral, or clinical fields. This grant is designed to encourage high-risk, high-reward research, providing funding for projects that are distinct from traditional R01 grants, with a maximum budget of $275,000 over a two-year period, and no more than $200,000 in any single year. Eligible applicants include a wide range of organizations such as educational institutions, nonprofit organizations, and tribal governments, with applications undergoing a rigorous peer review process to assess their innovation and feasibility. Interested parties should note that the application submission period begins on January 16, 2025, with the opportunity closing on January 7, 2028; for further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.